TICKERNERD
Menu
XNCRXNCRHealthcare · Biotechnology

XNCR Stock Forecast: Xencor, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$24
+0.62% on the day

The 14 Wall Street analysts covering Xencor, Inc. hold a median 12-month price target of $30 — +22.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$1.8B
Ticker Nerd rank
79 / 100
Median analyst target
$30
Analysts covering
14
Revenue$51.2M+17.5% y/y
Operating income−$37.1M
Net income−$21.7M
Free cash flow−$56.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.3%
1M
+10.5%
YTD
+59.4%
1Y
+187.2%
From 52W high
−16.7%
From 52W low
+187.5%
$8
$29
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XNCR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Xencor, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
79 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
87
Revisions
77
Issuance
73
Volatility
71
Value
65
Quality
63
Accruals
58
Size
38
Growth
34

Momentum (87): The shares have been drifting up relative to others.

Growth (34): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

XNCR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XNCR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26XNCRHigh $46Median $30Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
12 Buy2 Hold0 Sell
Low $20Median $30High $46

The green dot is the last close — the median target sits +22.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
11 Sept 2026BarclaysMaintainsOverweight$27 → $35
3 Sept 2026JP MorganMaintainsNeutral—
3 Sept 2026JP MorganMaintainsNeutral$14 → $21
1 Sept 2026Raymond JamesMaintainsStrong Buy—
1 Sept 2026Raymond JamesMaintainsStrong Buy$40 → $46
6 Aug 2026Cantor FitzgeraldMaintainsOverweight—
6 Aug 2026Cantor FitzgeraldMaintainsOverweight$43 → $44
6 Aug 2026RBC CapitalMaintainsOutperform—
6 Aug 2026RBC CapitalMaintainsOutperform$19 → $20
6 Aug 2026WedbushMaintainsOutperform$26 → $30
6 Aug 2026WedbushMaintainsOutperform—
30 July 2026WedbushReiteratesOutperform$26
30 July 2026WedbushReiteratesOutperform—
7 July 2026Truist SecuritiesMaintainsBuy—
7 July 2026Truist SecuritiesMaintainsBuy$29 → $27
11 May 2026JP MorganMaintainsNeutral—
24 Mar 2026JP MorganDowngradeNeutral—
26 Feb 2026BarclaysMaintainsOverweight—
17 Dec 2025BarclaysMaintainsOverweight—
24 Nov 2025Truist SecuritiesInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XNCR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

XNCR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Xencor, Inc. returned +187.2% against +17.5% for the S&P 500, dividends included.

XNCR vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300350Oct 25Jan 26Apr 26Jul 26XNCRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XNCR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

Xencor, Inc. (XNCR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−19.7×

Cheaper than 96% of US stocks

Price / sales
17.3×

Cheaper than 10% of US stocks

Price / book
3.6×

Cheaper than 28% of US stocks

EV / EBITDA
−7.4×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
17.5%

Higher than 66% of US stocks

Earnings growth (YoY)
17.5%

Higher than 55% of US stocks

Gross margin
—
Operating margin
−72.4%

Higher than 15% of US stocks

Net margin
−155.6%

Higher than 4% of US stocks

Returns & dividend
Return on equity
−29.1%

Higher than 27% of US stocks

Return on assets
−16.8%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Xencor, Inc. (XNCR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Xencor, Inc. has a market value of $1.8B and an enterprise value of $1.5B.

  • Revenue in the twelve months to 30 June 2026: $105.0M. The latest quarter grew 17.5% year on year.

  • Net income over the same four quarters: −$163.3M, a −155.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.17.

  • Free cash flow in the twelve months to 30 June 2026: −$208.3M.

  • Shares outstanding: 74.3M.

  • Trailing P/E: −19.7×; forward P/E: −6.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Xencor, Inc. employs 260 people — $404K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

XNCR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XNCRXencor, Inc.$1.8B
79
SEPNSepterna, Inc.$1.7B
90
KLRAKailera Therapeutics, Inc.$1.7B
1
KARDKardigan, Inc.$1.7B
0
DMRADamora Therapeutics, Inc.$1.7B
45
VIRVir Biotechnology, Inc.$1.8B
94
STOKStoke Therapeutics, Inc.$1.8B
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Xencor, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XNCR news & analysis

Xencor to Present at the 2026 Cantor Global Healthcare Conference

Business Wire · 2 Sept 2026neutral

Xencor, Inc. announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT. A live webcast of the presentation will be available in the Investors section of Xencor's website.

Why it matters — The presentation gives XNCR watchers an opportunity to hear directly from company management about its clinical-stage antibody programs for cancer and autoimmune diseases.

Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 5 Aug 2026positive

Xencor reported a second-quarter loss of $0.29 per share, which was narrower than the Zacks Consensus Estimate of a loss of $0.82 and the $0.41 per-share loss reported a year ago. The results beat revenue estimates.

Why it matters — A narrower-than-expected quarterly loss and revenue beat could signal improving financial performance for Xencor investors tracking the company's results.

Xencor Reports Second Quarter 2026 Financial Results

Business Wire · 5 Aug 2026positive

Xencor reported its financial results for the second quarter ended June 30, 2026. President and CEO Bassil Dahiyat said the company is excited to present XmAb819 results at ESMO this fall along with other fast-approaching milestones across its wholly owned clinical pipeline.

Why it matters — The news highlights upcoming clinical data and pipeline milestones for Xencor's wholly owned programs, which are relevant events for XNCR shareholders to watch.

Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter

Business Wire · 29 July 2026positive

Xencor announced a Settlement Agreement with Alexion to resolve a commercial dispute related to U.S. royalties on Ultomoris (ravulizumab-cwvz). Under the agreement, Xencor will receive a payment from Alexion.

Why it matters — The resolution of this royalty dispute and the resulting payment provide clarity on a financial overhang for Xencor.

FAQ

Frequently asked questions about XNCR stock

What is the XNCR stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Xencor, Inc. have a median 12-month price target of $30, with estimates ranging from $20 to $46. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XNCR stock a buy right now?

Of the 14 analysts covering Xencor, Inc., 12 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xencor, Inc. 79 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XNCR?

As at 12 Sept 2026, Xencor, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (87 of 100).

Will XNCR stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +22.9% from the last close, and Ticker Nerd's factor model ranks Xencor, Inc. 79 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XNCR stock forecast for 2030?

No analyst covering Xencor, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XNCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $46 over the next 12 months.

How has XNCR stock performed over the past year?

Xencor, Inc. returned +187.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Xencor, Inc. do?

Xencor Inc. is a clinical-stage biopharmaceutical company focused on designing and developing engineered antibody therapeutics for cancer, autoimmune disorders, and other serious diseases.

What is the latest news on XNCR?

The most recent item we track (Business Wire, 2 Sept 2026): "Xencor to Present at the 2026 Cantor Global Healthcare Conference". Xencor, Inc. announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT. A live webcast of the presentation will be available in the Investors section of Xencor's website.

Company

About Xencor, Inc.

Xencor Inc. is a clinical-stage biopharmaceutical company focused on designing and developing engineered antibody therapeutics for cancer, autoimmune disorders, and other serious diseases. The company’s XmAb protein engineering platform is used to create next-generation antibodies and bispecific molecules with tailored biological activity, supporting a portfolio of proprietary and partnered programs in clinical development. Xencor’s work centers on protein engineering that can improve how therapies interact with immune targets and disease pathways, making it a specialized participant in modern antibody drug innovation. The company also collaborates with external partners to apply its platform across multiple therapeutic areas, including oncology and immunology. Headquartered in Pasadena, California, Xencor Inc. operates as a biotechnology company whose current business is built around research, development, and collaboration in advanced biologic medicines.

CEO Dr. Bassil I. Dahiyat Ph.D. · 260 employees · United States · https://www.xencor.com